PerkinElmer Demonstrates the Benefits of High Throughput Screening Platforms to Interrogate Physiologically Relevant Models

Share Article

Through this webinar, which LabRoots will host November 16, attendees will learn the importance to scaling 3D models to a higher throughput format for higher throughput screening of drug candidates.

Madhu Nag, PhD Lead, Trans-NIH RNAi Facility Division of Pre-Clinical Innovation National Center for Advancing Translational Sciences National Institutes of Health

The wide use of 2D monolayer cultures for cancer drug discovery reflects the technical ease of implementation for drug screening, and the view that oncogenes or tumor suppressor genes are the key genetic drivers of cancer cell proliferation, and therefore, inhibiting these tumor driver genes with drugs should prevent tumor growth.

However, there is now ample evidence that the cellular and physiological context in which these oncogenic events occur play a key role in how they drive tumor growth in vivo, and therefore, in how a tumor responds to drug treatments. In vitro three dimensional (3D) spheroid cell culture tumor models are being developed to potentially enhance the predictability and efficiency of drug discovery in cancer.

Participants of this webinar will learn the application benefits of 3D models within oncology research and therapeutic strategies. They will learn from a comprehensive of mechanism of action data from 3D models to that generated from 2D systems.

The team at PerkinElmer has arranged for Dr. Madhu Nag, lead scientist at the Trans-NIH RNAi Facility Division of Pre-Clinical Innovation National Center for Advancing Translational Sciences National Institutes of Health, to be the speaker for this event.

Nag currently serves as the head of the Trans NIH RNAi Facility at the National Center for Advancing Translational Sciences (NCATS), which is responsible for developing and conducting genome wide physiologically relevant phenotypic assays for Intramural researchers. Prior to joining NCATS, she completed her postdoctoral fellowship at the National Institute on Aging. She earned her doctorate from the George Washington University in Molecular and Cellular Oncology. She has extensive experience in the miniaturization and optimization of physiologically relevant cell-based 2D and 3D assays.

LabRoots will host the webinar November 16, 2017, beginning at 9 a.m. PST, noon EST. To learn more about this event, the continuing education credits offered, or to register for free, click here.

About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader committed to innovating for a healthier world. The Company reported revenue of approximately $2.3 billion in 2015, has approximately 8,000 employees serving customers in more than 150 countries and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE or at http://www.perkinelmer.com.

About LabRoots
LabRoots is the leading scientific social networking website, which provides daily scientific trending news and science-themed apparel, as well as produces educational virtual events and webinars, on the latest discoveries and advancements in science. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Karen Sorenson
LabRoots, Inc.
+1 (619) 861-0590
Email >
Visit website